Loading news...
The Dow tapped a new record higher while other major indexes rose, thanks to a bounce back in tech and software stocks
Waters Corporation (WAT) Q4 2025 Earnings Call Transcript
Waters (WAT) came out with quarterly earnings of $4.53 per share, beating the Zacks Consensus Estimate of $4.5 per share. This compares to earnings of $4.1 per share a year ago.
FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE: WAT).
Announces appointment of Claire M. Fraser, Ph.D.
Stock News Japan rally on election landslide: Japanese stocks hit record highs after Prime Minister Sanae Takaichi's coalition secured a two-thirds lower-house
Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currency Growth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regions Chemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demand Instruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for Empower GAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digits Full-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in constant currency Instruments grew 5% in constant currency, led by strong LC-MS growth Recurring Revenue grew 8% in constant currency, led by 12% Chemistry growth GAAP EPS of $10.76; non-GAAP EPS of $13.13 grew double digits MILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the fourth quarter and full year 2025.
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters Corporation: Bigger, Better, But Fairly Priced
National Pension Service boosted its stake in Waters Corporation (NYSE: WAT) by 1.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 107,359 shares of the medical instruments supplier's stock after buying an additional 1,857 shares during the quarter. National Pension Service owned
New York State Common Retirement Fund decreased its holdings in shares of Waters Corporation (NYSE: WAT) by 18.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 39,941 shares of the medical instruments supplier's stock after selling 8,878 shares during the period. New York State Common
Tenon Medical (NASDAQ: TNON - Get Free Report) and Waters (NYSE: WAT - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Institutional and Insider Ownership 22.7% of Tenon Medical shares
Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026 FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business to BD's shareholders.
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.
MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m.
Deroy and Devereaux Private Investment Counsel Inc. grew its holdings in shares of Waters Corporation (NYSE: WAT) by 41.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,802 shares of the medical instruments supplier's stock after buying an additional
US forces seized an oil tanker, the Veronica, near Venezuela on Thursday morning as part of a crackdown on a global shadow fleet used to export sanctioned crude. https://www.bloomberg.com/news/articles/2026-01-15/us-seizes-sixth-oil-tanker-in-waters-around-venezuela?sref=omvmmwIg
Representative Julia Letlow (R-Louisiana) recently sold shares of AbbVie Inc. (NYSE: ABBV). In a filing disclosed on January 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on December 8th. The trade occurred in the Representative's "MERRILL LYNCH INVESTMENT ACCOUNT #025" account. Representative Julia Letlow also recently made the following
Representative Julia Letlow (R-Louisiana) recently bought shares of United Rentals, Inc. (NYSE: URI). In a filing disclosed on January 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in United Rentals stock on December 16th. The trade occurred in the Representative's "MERRILL LYNCH INVESTMENT ACCOUNT #025" account. Representative Julia Letlow also recently made
Representative Julia Letlow (R-Louisiana) recently bought shares of AstraZeneca PLC (NASDAQ: AZN). In a filing disclosed on January 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on December 8th. The trade occurred in the Representative's "MERRILL LYNCH INVESTMENT ACCOUNT #025" account. Representative Julia Letlow also recently made the following